(RTTNews) - Celltrion, Inc. (068270.KS), a biopharmaceutical company, reported a decline in net income on Tuesday despite higher third-quarter 2026 sales than the previous year.
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.